Evolving Treatment Paradigms in Hepatocellular Carcinoma
Nov
12
2023
Ballroom BC
-
Hynes Convention Center
4:30
- 6:00 PM EST
Speakers
Description
Abstracts
- ANTICANCER EFFECTS OF VITAMIN K COMBINED WITH TRANSARTERIAL CHEMOEMBOLIZATION IN HEPATOCELLULAR CARCINOMA; A PROSPECTIVE, RANDOMIZED TRIAL.
- MOLECULAR SIGNATURE OF PERIPHERAL CIRCULATING TUMOR CELLS IN CANCER PROGRESSION OF HEPATOCELLULAR CARCINOMA PATIENTS TREATED BY ATEZOLIZUMAB PLUS BEVACIZUMAB
- FOUR-YEAR OVERALL SURVIVAL UPDATE FROM THE PHASE 3 HIMALAYA STUDY OF TREMELIMUMAB PLUS DURVALUMAB IN UNRESECTABLE HEPATOCELLULAR CARCINOMA
- RECURR-NET, A MULTIPHASIC DEEP LEARNING MODEL, IS SUPERIOR TO MICROVASCULAR INVASION IN PREDICTING HEPATOCELLULAR CARCINOMA RECURRENCE AFTER CURATIVE SURGERY: RESULTS FROM INTERNAL VALIDATION AND EXTERNAL TESTING
- COMPARISON OF RECURRENCE PREDICTION MODELS AND IMBRAVE 050 CRITERIA TO SELECT PATIENTS FOR ADJUVANT IMMUNOTHERAPY AFTER CURATIVE RESECTION OF HEPATOCELLULAR CARCINOMA
- ANALYSIS OF IMMUNE-RELATED ADVERSE EVENTS AND TIME-TO-TREATMENT DISCONTINUATION OF ATEZOLIZUMAB AND BEVACIZUMAB IN PATIENTS WITH HEPATOCELLULAR CARCINOMA: A MULTICENTER COHORT STUDY